Bayesian Capital Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Bayesian Capital Management’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-66,900	Closed	-$452K	–	919
2024 Q4	$452K	Buy	+66,900	New	+$450K	0.06%	391
2024 Q3	–	Sell	-42,400	Closed	-$318K	–	995
2024 Q2	$318K	Buy	+42,400	New	+$370K	0.04%	491
2023 Q4	–	Sell	-59,611	Closed	-$456K	–	995
2023 Q3	$456K	Buy	+59,611	New	+$595K	0.05%	392
2023 Q2	–	Sell	-24,095	Closed	-$161K	–	1029
2023 Q1	$161K	Sell	24,095 -37,300	-61%	-$296K	0.02%	637
2022 Q4	$473K	Buy	+61,395	New	+$602K	0.07%	372
2022 Q2	–	Sell	-25,700	Closed	-$184K	–	1039
2022 Q1	$184K	Buy	+25,700	New	+$273K	0.03%	663

Other funds holding RXRX

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MIC

Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Bayesian Capital Management's RXRX Position: Q1 2025 in Review

Bayesian Capital Management sold out of Recursion Pharmaceuticals (RXRX) in Q1 2025, closing a stake of 66,900 shares — an estimated $452K sold.

Bayesian Capital Management first reported a position in RXRX in Q1 2022 and held it in 6 quarters. The position peaked at $473K in Q4 2022. 336 funds tracked by Wall St. Rank hold RXRX as of Q1 2025.

Bayesian Capital Management reported no remaining Recursion Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Bayesian Capital Management sold 66,900 Recursion Pharmaceuticals shares in Q1 2025, an estimated $452K.
Bayesian Capital Management first reported a position in Recursion Pharmaceuticals in Q1 2022 and held it in 6 quarters.
Bayesian Capital Management's Recursion Pharmaceuticals position peaked at $473K in Q4 2022.
336 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2025.

Based on Bayesian Capital Management's 13F filing for Q1 2025, filed 15 May 2025.